Below is an overview of how the two compare: Mechanism of Action: Retatrutide: Triple agonist (GLP-1, GIP, glucagon) Zepbound: Dual agonist (GLP-1, GIP) Developer: Retatrutide: Eli Lilly and Company (investigational) Zepbound: Eli Lilly and Company (approved) Regulatory Status: Retatrutide: Phase III clinical development Zepbound: FDA-approved for obesity, obstructive sleep apnea Weight Loss Efficacy: Retatrutide: Up to ~28.7% (68 weeks

The attorneys general identified the following concerns including: Counterfeit semaglutide imported from China, Turkey and India and repackaged as FDA-approved products Online sellers promoting research-only peptides while providing instructions for human injection Consumers mixing raw powders at home, leading to overdoses, contamination and serious adverse events Compounding pharmacies operating around legal boundaries, including insanitary conditions and high-impurity formulations Risks of hospitalization tied to dosing errors and adulterated ingredients The attorneys general asked the FDA and the Department of Homeland Security to take joint action to intercept illegal imports and protect patient safety
Just how GLP-1 drugs cause headaches isnt fully understood
The near-term battle is now moving into pills
Currently in Phase 3 clinical trials under Eli Lilly, retatrutide is not FDA-approved and cannot be prescribed through standard pharmacies